Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1970 1
1982 1
1993 1
1998 1
2000 1
2001 1
2002 2
2003 1
2005 3
2006 1
2007 2
2008 15
2009 8
2010 8
2011 10
2012 16
2013 16
2014 22
2015 13
2016 16
2017 14
2018 21
2019 21
2020 46
2021 23
2022 36
2023 34
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

310 results

Results by year

Filters applied: . Clear all
Page 1
Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia.
Hu CL, Chen BY, Li Z, Yang T, Xu CH, Yang R, Yu PC, Zhao J, Liu T, Liu N, Shan B, Zhang Q, Song J, Fei MY, Zong LJ, Zhang JY, Wu JC, Chen SB, Wang Y, Chang B, Hou D, Liu P, Jiang Y, Li X, Chen X, Deng CH, Ren YY, Wang R, Jin J, Xue K, Zhang Y, Du M, Shi J, Wu LY, Chang CK, Shen S, Chen Z, Chen SJ, Liu X, Sun XJ, Zheng M, Wang L. Hu CL, et al. Among authors: fei my. Cell Res. 2022 Dec;32(12):1105-1123. doi: 10.1038/s41422-022-00735-6. Epub 2022 Oct 27. Cell Res. 2022. PMID: 36302855 Free PMC article.
Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
Zhou Y, Fei M, Zhang G, Liang WC, Lin W, Wu Y, Piskol R, Ridgway J, McNamara E, Huang H, Zhang J, Oh J, Patel JM, Jakubiak D, Lau J, Blackwood B, Bravo DD, Shi Y, Wang J, Hu HM, Lee WP, Jesudason R, Sangaraju D, Modrusan Z, Anderson KR, Warming S, Roose-Girma M, Yan M. Zhou Y, et al. Among authors: fei m. Immunity. 2020 Feb 18;52(2):357-373.e9. doi: 10.1016/j.immuni.2020.01.014. Epub 2020 Feb 11. Immunity. 2020. PMID: 32049051 Free article.
The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment.
Fei MY, Wang Y, Chang BH, Xue K, Dong F, Huang D, Li XY, Li ZJ, Hu CL, Liu P, Wu JC, Yu PC, Hong MH, Chen SB, Xu CH, Chen BY, Jiang YL, Liu N, Zhao C, Jin JC, Hou D, Chen XC, Ren YY, Deng CH, Zhang JY, Zong LJ, Wang RJ, Gao FF, Liu H, Zhang QL, Wu LY, Yan J, Shen S, Chang CK, Sun XJ, Wang L. Fei MY, et al. Blood. 2023 Sep 7;142(10):903-917. doi: 10.1182/blood.2022019537. Blood. 2023. PMID: 37319434 Free PMC article.
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME. Hourigan CS, et al. Among authors: fei m. J Clin Oncol. 2020 Apr 20;38(12):1273-1283. doi: 10.1200/JCO.19.03011. Epub 2019 Dec 20. J Clin Oncol. 2020. PMID: 31860405 Free PMC article.
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.
Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME. Scott BL, et al. Among authors: fei m. Transplant Cell Ther. 2021 Jun;27(6):483.e1-483.e6. doi: 10.1016/j.jtct.2021.02.031. Epub 2021 Feb 26. Transplant Cell Ther. 2021. PMID: 33775615 Free PMC article. Clinical Trial.
Differential Human Learning Optimization Algorithm.
Zhang P, Wang L, Du J, Fei Z, Ye S, Fei M, Pardalos PM. Zhang P, et al. Among authors: fei m. Comput Intell Neurosci. 2022 Apr 30;2022:5699472. doi: 10.1155/2022/5699472. eCollection 2022. Comput Intell Neurosci. 2022. PMID: 35535198 Free PMC article.
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Bolaños-Meade J, et al. Among authors: fei m. Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7. Lancet Haematol. 2019. PMID: 30824040 Free PMC article. Clinical Trial.
310 results